MedWorm: Crestor

  ACC: Chronic Kidney Disease Patients Fare Well in Statin Trial (CME/CE)

ATLANTA (MedPage Today) -- Chronic kidney disease patients in the landmark JUPITER trial achieved a 44% reduction in mortality if they were assigned to the potent cholesterol-lowering agent rosuvastatin (Crestor) when compared with patients who were on placebo, researchers said here. (Source: MedPage Today Cardiovascular)

top  

  Rosuvastatin cuts LDL-C in children with familial hypercholesterolemia

Rosuvastatin therapy significantly reduces levels of low-density lipoprotein cholesterol and is well-tolerated in adolescents with familial hypercholesterolemia, a randomized placebo-controlled trial has found. (Source: MedWire News - Lipidology)

top  

  Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells.

In conclusion, we show that rosuvastatin had significant stimulatory effects on EPCs irrespectively of the culture protocol. Rosuvastatin also induced anti-inflammatory polarization of monocytic EPCs. PMID: 20233166 [PubMed - as supplied by publisher] (Source: Cell Biology International)

top  

  Clinical Significance of Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER) Trial

(Source: AccessMedicine Updates)

top  

  ACC: Triglycerides Decreased with Rosuvastatin Therapy (CME/CE)

ATLANTA (MedPage Today) -- In a study that specifically scrutinized the effects of statin therapy on triglycerides, researchers said that rosuvastatin (Crestor) significantly reduced the blood lipid that has been linked to coronary artery disease better than placebo. (Source: MedPage Today Cardiovascular)

top  

  ACC: Rosuvastatin Plus Fenofibric Acid Treatment Maintains Potency (CME/CE)

ATLANTA (MedPage Today) -- Two years after beginning lipid-lowering therapy with an investigative treatment combining rosuvastatin (Crestor) with fenofibric acid (Trilipix), researchers said patients maintained an improved lipid profile -- and patients did not develop new adverse events. (Source: MedPage Today Cardiovascular)

top  

  ACC: Rosuvastatin and Ezetimibe Combo Tops LDL Trial (CME/CE)

ATLANTA (MedPage Today) -- More than 95% of patients taking a high dose rosuvastatin (Crestor) plus ezetimibe (Zetia) combination reached low-density lipoprotein (LDL) goals of less than 100 mg/dl -- a significant improvement over a high-dose combination of simvastatin/ezetimibe (Vytorin), researchers said here. (Source: MedPage Today Cardiovascular)

top  

  Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

This study was undertaken to evaluate the efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.Background: Familial hypercholesterolemia is a common inherited disorder causing markedly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth and resulting in premature atherosclerosis. In children, statins have been shown to be effective in reducing LDL-C, restoring flow-mediated dilation, and slowing carotid intima-media thickening. However, few children in these trials achieved current LDL-C goals.Methods: This study comprised a 12-week double-blind, randomized, placebo-controlled trial, followed by a 40-week open-label, titration-to-goal extension phase in 177 pubertal children, ages 10 to 17 years, with familial hypercholesterolemia. ...

top  

  Prevention of Peri-procedural Myocardial Injury Using a Single High Loading Dose of Rosuvastatin

Conclusion  A single high loading dose of rosuvastatin reduces the incidence of peri-procedural myocardial necrosis and infarction effectively. Content Type Journal ArticleDOI 10.1007/s10557-010-6224-1Authors Serkan Cay, Yuksek Ihtisas Heart-Education and Research Hospital Department of Cardiology Ankara TurkeyGoksel Cagirci, Ministry of Health Dışkapı Yıldırım Beyazıt Research and Educational Hospital Department of Cardiology Ankara TurkeyNihat Sen, Mustafa Kemal University, Faculty of Medicine Department of Cardiology Hatay TurkeyYucel Balbay, Yuksek Ihtisas Heart-Education and Research Hospital Department of Cardiology Ankara TurkeyTahir Durmaz, Ataturk Education and Research Hospital Department of Cardiology Ankara TurkeySinan Aydogdu, Yuksek Ihtisas Heart-Edu...

top  

  Rosuvastatin effective for primary prevention in CKD patients

Rosuvastatin treatment is effective for the prevention of first cardiovascular events and all-cause mortality in people with elevated levels of C-reactive protein and moderate chronic kidney disease, a subanalysis of JUPITER suggests. (Source: MedWire News - Lipidology)

top  

  Journal Scan: Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia (J Am Coll Cardiol 2010;55:1121-1126.)

A 12-week, double-blind, randomized, placebo-controlled trial was performed, followed by a 40-week open-label extension phase. A total of 177 children (mean age 14.5 years) were enrolled, and were randomized either to placebo or rosuvastatin 5, 10, or 20 mg daily. (Source: Cardiosource)

top  

  Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein: A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention–an Intervention Trial Evaluating Rosuvastatin) Trial

Objectives: We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kidney disease (CKD).Background: Whether patents with moderate CKD (estimated glomerular filtration rate [eGFR] (Source: Journal of the American College of Cardiology)

top  

  Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)

BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors.  But sometimes there is a much larger bit of data either north of the border or in Europe.  There is a company called  Resverlogix Corp. which trades in Canada under the ticker ‘RVX’ and the stock also trades in the US on the Pink Sheets under the ticker ‘RVXCF.’  The stock is soaring today after Bloomberg gave a very positive article highlighting the merits of the company’s RVX-208.  This potential drug candidate is targeting atherosclerosis in acute coronary syndrome patients.  The target is to raise HDL levels to effectively reverse arterial plaque buildup.  The company noted that there are approximately 350 million patients that require treatment for atheroscl...

top  

  Rosuvastatin Protects Against Reperfusion-Related Damage

Rosuvastatin protects against injury from ischemia and reperfusion through a cyclooxygenase-2-dependent mechanism, which may explain why cyclooxygenase-2 inhibitors have negative cardiovascular side-effects, according to a study in the March 9 issue of the Journal of the American College of Cardiology. (Source: Modern Medicine)

top  

  Rosuvastatin Beneficial for Patients With Kidney Disease and Elevated CRP

In patients with moderate kidney disease and elevated high-sensitivity C-reactive protein, rosuvastatin helps reduce cardiovascular events and all-cause mortality, new research shows. Reuters Health Information (Source: Medscape Medical News Headlines)

top  

  Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2–Dependent Mechanism

Conclusions: Rosuvastatin pharmacologically prevents the development of IR-induced conduit artery endothelial dysfunction. This beneficial effect of rosuvastatin is mediated by a COX-2–dependent mechanism, evidence that may also provide potential mechanistic insight into the reported cardiotoxic effects of COX-2 inhibitors. (Source: Journal of the American College of Cardiology)

top  

  Statin Reduces Cardiovascular Events, Mortality in CKD

Rosuvastatin (Crestor) reduces all-cause mortality and the incidence of first cardiovascular events among subjects with moderate chronic kidney disease, low-density lipoprotein cholesterol of less than 130 mg/dL, and elevated high-sensitivity C-reactive protein, according to research published online March 3 in the Journal of the American College of Cardiology. (Source: Modern Medicine)

top  

  Interpreting The JUPITER Trial: Statins can prevent VTE, but more study is needed

The incidence of venous thromboembolism in people taking rosuvastatin (Crestor) 20 mg/day was about half that in people taking placebo. This was a relatively healthy population, and the incidence in both groups was low. (Source: Cleveland Clinic Journal of Medicine)

top  

  COX-2 Inhibitors Blunt "Preconditioning" Effect of Statin

The COX-2 inhibitor celecoxib completely abolished the beneficial preconditioning effect of rosuvastatin in a small mechanistic study in human volunteers. Heartwire (Source: Medscape Medical News Headlines)

top  

  COX-2 inhibitors blunt "preconditioning" effect of statin

The COX-2 inhibitor celecoxib completely abolished the beneficial preconditioning effect of rosuvastatin in a small mechanistic study in human volunteers. For complete story visit theheart.org. (Source: theHeart.org)

top  

  Statins for Prevention? Taking a Cholesterol-Lowering Drug When Cholesterol Is Normal

Crestor OK’d for broader use; FDA says those with normal cholesterol but high inflammation now qualify. (Source: U.S. News - Health)

top  

  Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.

CONCLUSIONS: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals. PMID: 20195400 [PubMed - in process] (Source: The Korean Journal of Internal Medicine)

top  

  FDA Approves Statin for Primary Prevention

In addition to its other approved indications, rosuvastatin can now be used as a primary prevention in reducing the risk of myocardial infarction, stroke, and arterial revascularization procedures. (Source: Cardiology News)

top  

  Exploring new indications for statins beyond atherosclerosis: Successes and setbacks.

In conclusion, although statins are effective, established therapy for the prevention of vascular events in patients at risk, they have as yet not proven to be successful for these newer indications. PMID: 20206067 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)

top  

  Rosuvastatin Approved For Primary Prevention

Rosuvastatin can now be used as a primary prevention in reducing the risk of myocardial infarction, stroke, and arterial revascularization procedures. This is the first Food and Drug Administration–approved indication for a cholesterol-lowering drug to treat patients who don't have elevated cholesterol levels. It could also be seen as the agency's first endorsement of high-sensitivity C-reactive protein (hsCRP) as a cardiovascular risk factor. (Source: Clinical Endocrinology News)

top  

  CRESTOR (Rosuvastatin Calcium) Tablet, Film Coated [AstraZeneca Pharmaceuticals LP]

Updated Date: Feb 24, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  New Analysis of Jupiter Data Finds Statin Therapy For Apparently Healthy Women Significantly Reduced Risk For Cardiovascular Events

Women with acceptable levels of bad cholesterol but elevated high sensitivity C-reactive protein levels benefitted greatly from a daily regimen of rosuvastatin. (Source: BWH for Journalists)

top  

  New Analysis of Jupiter Data Finds Statin Therapy For Apparently Healthy Women Significantly Reduced Risk For Cardiovascular Events

Women with acceptable levels of bad cholesterol but elevated high sensitivity C-reactive protein levels benefitted greatly from a daily regimen of rosuvastatin. (Source: BWH News)

top  

  Pitavastatin: A New HMG-CoA Reductase Inhibitor(March) (CE).

CONCLUSIONS: In light of the lack of outcome data, pitavastatin offers no clear advantage over other drugs in this class. PMID: 20179258 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

top  

  Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials.

Conclusion-JUPITER demonstrated that in primary prevention rosuvastatin reduced CVD events in women with a relative risk reduction similar to that in men, a finding supported by meta-analysis of primary prevention statin trials. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681. PMID: 20176986 [PubMed - as supplied by publisher] (Source: Circulation)

top  

  CRESTOR (Rosuvastatin Calcium) Tablet, Film Coated [Physicians Total Care, Inc.]

Updated Date: Feb 18, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  C-reactive protein (CRP) associated with risk of coronary heart disease, stroke, vascular mortality, and death from several cancers and lung disease

Associations of C-reactive protein (CRP) concentration with risk of major diseases can best be assessed by long-term prospective follow-up of large numbers of people. This Lancet meta-analysis included records of 160,309 people without a history of vascular disease from 54 long-term prospective studies. Risk ratios (RRs) were 1·23 for coronary heart disease; 1·32 for ischaemic stroke; 1·34 for vascular mortality; and 1·34 for non-vascular mortality. CRP concentration has continuous associations with the risk of: - coronary heart disease - ischaemic stroke - vascular mortality - death from several cancers and lung disease The relevance of CRP to such a range of disorders is unclear. Associations with ischaemic vascular disease depend considerably on conventional risk fact...

top  

  CRESTOR (Rosuvastatin Calcium) Tablet, Film Coated [AstraZeneca Pharmaceuticals LP]

Updated Date: Feb 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  Rosuvastatin approved by US FDA for primary prevention of CVD

The US Food and Drug Administration has approved rosuvastatin for use in primary prevention of cardiovascular disease, the first statin to be approved for this indication. (Source: MedWire News - Lipidology)

top  

  Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers.

This study demonstrates the value of monitoring the plasma pharmacokinetics of the inhibitor, and not only the drug under investigation, to improve the mechanistic interpretation. PMID: 20150523 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Pharmacology)

top  

  FDA Approves New Indication For Crestor

On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it. The new indication is for reducing the likelihood of a heart attack or stroke or the need for a procedure to treat blocked or narrowed arteries in patients who have never been told they have heart disease but are nevertheless at increased risk of a cardiac event... (Source: Health News from Medical News Today)

top  

  FDA Approves New Indication For Crestor

On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it... (Source: Cardiovascular / Cardiology News From Medical News Today)

top  

  US FDA Approves New Indication For CRESTOR® (rosuvastatin Calcium)

AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men â�¥50 and women â�¥60), high-sensitivity C-reactive protein (hsCRP) â�¥ 2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family hist... (Source: Health News from Medical News Today)

top  

  US FDA Approves New Indication For CRESTOR® (Rosuvastatin Calcium)

AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men... (Source: Cardiovascular / Cardiology News From Medical News Today)

top  

  FDA Approves New Indication for Crestor

Source: Food and Drug Administration Related MedlinePlus Topic: Cholesterol (Source: MedlinePlus Health News)

top  

  Dispatch: Preemptive Drugs, Autism, Radiotherapy

On Monday the FDA approved AstraZeneca& rsquo;s Crestor for men over 50 and women over 60 who have & ldquo;high-sensitivity C-reactive protein... (Source: Health Facts and Fears)

top  

  CVN: FDA Approves

FDA Approves Rosuvastatin for High CRP (Source: Cardiosource)

top  

  US FDA Approves New Indication for Crestor (Rosuvastatin Calcium)

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) (Source: World Pharma News)

top  

  FDA approves rosuvastatin for primary prevention of cardiovascular disease

Source: FDA Area: News The U.S. Food and Drug Administration (FDA) has approved rosuvastatin (CrestorT) for the primary prevention of cardiovascular disease to reduce the risk of stroke, heart attack, and the risk of arterial revascularisation procedures (including coronary artery bypass graft, or bypass grafting of a peripheral artery or carotid artery, or angioplasty or stent placement) in individuals who have no clinically evident heart disease but are at an increased risk of heart disease due to the combined effect of the following risk factors: . Age (> 50 years in men; > 60 years in women), and . An elevated high-sensitivity C-reactive protein level (> 2 mg/L), and . Presence of at least one additional cardiovascular risk factor (e.g., high blood pressure, ...

top  

  Crestor Approval Expanded

(Source: Modern Medicine)

top  

  FDA Approves New Indication for Crestor

On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it. The new indication is for reducing the likelihood of a heart attack or stroke or the need for a procedure to treat blocked or narrowed arteries in patients who have never been told they have heart disease but are nevertheless at increased risk of a cardiac event. (Source: Food and Drug Administration)

top  

  FDA Approves New Indication for Crestor

On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it. The new indication is for reducing the likelihood of a heart attack or stroke or the need for a procedure to treat blocked or narrowed arteries in patients who have never been told they have heart disease but are nevertheless at increased risk of a cardiac event. (Source: Food and Drug Administration)

top  

  FDA Approves Expanded Rosuvastatin Label

The FDA's decision was announced late Monday. Heartwire (Source: Medscape Medical News Headlines)

top  

  FDA Expands Rosuvastatin Use to People With Normal LDL

The FDA's decision was announced late Monday. Heartwire (Source: Medscape Today Headlines)

top  

  AstraZneca Gets OK for Expanded Crestor Use

From Associated Press (February 9, 2010) WASHINGTON -- Federal regulators have granted Anglo-Swedish drug maker AstraZeneca approval to market its cholesterol pill Crestor as a preventive measure against heart attack and stroke in patients with... (Source: Drugs.com - Pharma News)

top  

  FDA Move May Bolster Crestor

The U.S. Food and Drug Administration's approval of AstraZeneca's cholesterol drug Crestor for a new group of patients could open a large new market for the drug. (Source: WSJ.com: Health)

top  

  FDA Approves Expanded Use of Crestor

(Source: Physician's First Watch current issue)

top  

  FDA Approves Crestor to Reduce Stroke, Heart Attack Risk

Approval based on JUPITER study which evaluated Crestor in a previously unstudied population WILMINGTON, Del., Feb. 8 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Crestor... (Source: Drugs.com - New Drug Approvals)

top  

  Health News of the Day

is a daily summary made from the selected links I post on Twitter. It is in bullet-point format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day: Spending on health care in US is 17.3% of GDP, up from 16.2% in 2008 - largest percentage increase in 5 decades http://goo.gl/IZE4 People who drank 2 or more soft drinks a week had an 87% increased risk of pancreatic cancer http://goo.gl/DcXd Thirdhand Smoke (tobacco smoke residue) Creates Indoor Cancer Risk. Nicotine reacts with indoor air pollutant to form carcinogenic compounds called tobacco-specific nitrosamines (TSNAs) http://bit.ly/cRpb4r Mediterranean diet may help prevent dementia - CNN http://bit.ly/a9lGLb Latrepirdine (Dimebon) - oral medication developed for Alzheimer's - may ...

top  

  FDA Okays Statin for Primary Prevention

WASHINGTON --The FDA has approved rosuvastatin (Crestor) for primary prevention of cardiovascular disease, making it the first statin to receive this indication. (Source: MedPage Today Cardiovascular)

top  

  FDA OKs Astra’s Crestor for preventive care

The FDA has approved a new indication for the cholesterol lowering medication Crestor (rosuvastatin, AstraZeneca) to be used preventatively in people with particular heart disease risk factors. (Source: Cardiovascular Business News)

top  

  Crestor Wins Approval as a Drug to Prevent Heart Disease

The Food and Drug Administration cleared the way for the cholesterol treatment to be used by millions of people who are not normally prescribed such drugs. (Source: NYT > Health)

top  

  FDA approves expanded rosuvastatin label

The FDA's decision was announced late Monday. For complete story visit theheart.org. (Source: theHeart.org)

top  

  AstraZeneca gets OK for expanded Crestor use

Federal regulators have granted AstraZeneca approval to market its cholesterol pill Crestor as a preventive measure against heart ... (Source: USATODAY.com Health)

top  

  FDA Widens Crestor Approval

The Food and Drug Administration Monday approved wider use of Crestor, AstraZeneca PLC's cholesterol-lowering drug, allowing the company to market the drug to patients who don't have signs of heart disease. (Source: WSJ.com: Health)

top  

  Reversal of age-associated memory impairment by rosuvastatin in rats.

Authors: Rech RL, Lima MN, Dornelles A, Garcia VA, Alcalde LA, Vedana G, Schröder N Increased levels of iron in brain regions have been reported in neurodegenerative disorders as well as in normal brain aging. We have previously demonstrated that neonatal iron loading induces cognitive impairment in adult rats. Here, we evaluate the effects of neonatal iron treatment on cognition in aged rats. We also investigated the effects of a late subchronic rosuvastatin treatment on iron- and age-induced cognitive deficits. Rats received vehicle or 10.0 mg/kg Fe(+2) orally at postnatal days 12-14. When animals reached the age of 23 months, they received daily intraperitoneal injections of saline or rosuvastatin (0.2 or 2.0 mg/kg) for 21 days. Twenty-four hours after the last injection, they ...

top  

  ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin.

We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin. PMID: 20130569 [PubMed - as supplied by publisher] (Source: Clinical Pharmacology and Therapeutics)

top  

  Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia

(Source: American Journal of Cardiovascular Drugs)

top  

  AstraZeneca's Net Profit Rises

The U.K. drug maker reported a smaller-than-expected 24% increase in net profit, boosted by rising sales of cholesterol pill Crestor and its swine-flu vaccine. (Source: WSJ.com: Health)

top  

  Hyperlipoproteinaemia(a): which is the optimal therapy? A case report

This case report presents the clinical history of a patient with elevated lipoprotein(a) and small size isoform, associated with mixed hyperlipaemia, which was probably familial combined hyperlipaemia. After premature myocardial infarction, the subject was treated with fibrates. Niacin was started after recurrence. One year ago, after another episode of acute coronary syndrome, rosuvastatin was added to niacin. The atherogenicity of this lipid disorder, along with the different options for therapy is discussed. (Source: Journal of Clinical Pharmacy and Therapeutics)

top  

  One-Year Treatment with Rosuvastatin Reduces Intima-Media Thickness in 45 Hypercholesterolemic Subjects with Asymptomatic Carotid Artery Disease

Pharmacology 2010;85:63–67 (DOI:10.1159/000276476) (Source: Karger Publishers)

top  

  Rosuvastatin and Clinical Outcomes in Individuals Who are not Deemed Appropriate for Baseline Statin Therapy

Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s11883-009-0082-yAuthors Michael Clearfield, Touro University College of Osteopathic Medicine 1310 Johnson Lane, Mare Island Vallejo CA 94592 USA Journal Current Atherosclerosis ReportsOnline ISSN 1534-6242Print ISSN 1523-3804 (Source: Current Atherosclerosis Reports)

top  

  Rosuvastatin demonstrates efficacy in primary stroke prevention

Rosuvastatin treatment halves the incidence of ischemic stroke in people with normal lipid levels but elevated levels of C-reactive protein, a subanalysis of the JUPITER trial reveals. (Source: MedWire News - Cardiology)

top  

  Rosuvastatin demonstrates efficacy in primary stroke prevention

Rosuvastatin treatment halves the incidence of ischemic stroke in people with normal lipid levels but elevated levels of C-reactive protein, a subanalysis of the JUPITER trial reveals. (Source: MedWire News - Lipidology)

top  

  Rosuvastatin demonstrates efficacy in primary stroke prevention

Rosuvastatin treatment halves the incidence of ischemic stroke in people with normal lipid levels but elevated levels of C-reactive protein, a subanalysis of the JUPITER trial reveals. (Source: MedWire News - Stroke)

top  

  New Findings From JUPITER Show Rosuvastatin Cuts Stroke Risk in Half Among Those With Elevated CRP Levels and Commonly Acceptable Cholesterol Levels

Men and women with low levels of bad cholesterol but elevated levels of high-sensitivity C-reactive protein who were randomly given rosuvastatin, reduced their risk of fatal or non-fatal stroke by 48 percent. (Source: BWH for Journalists)

top  

  New Findings From JUPITER Show Rosuvastatin Cuts Stroke Risk in Half Among Those With Elevated CRP Levels and Commonly Acceptable Cholesterol Levels

Men and women with low levels of bad cholesterol but elevated levels of high-sensitivity C-reactive protein who were randomly given rosuvastatin, reduced their risk of fatal or non-fatal stroke by 48 percent. (Source: BWH News)

top  

  Effects of Rosuvastatin on Coronary Flow Reserve and Metabolic Mismatch in Patients With Heart Failure (from the CORONA Study)

In patients with heart failure (HF), statin treatment might improve myocardial perfusion, but could also have detrimental effects on myocardial metabolism. A predefined substudy of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial sought to determine the effects of statin treatment on myocardial blood flow reserve and cardiac metabolism. Sixteen patients with HF (New York Heart Association class II or III) were randomized to rosuvastatin 10 mg/day (n = 8) or placebo treatment (n = 8). At baseline and after 6 months of treatment, nitrogen-13 ammonia at rest and after dipyridamole stress and 18-fluorodeoxyglucose positron emission tomography were performed. Rosuvastatin treatment significantly lowered total (−36%, p (Source: The American Journal of Cardiology)

top  

  Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database

To detect adverse drug reaction (ADR) signals of rosuvastatin compared to other statins with a novel data-mining approach based on relative risk (RR) using the national health insurance claims database, and to evaluate the usefulness of this method as a tool for signal detection.We used the Health Insurance Review & Assessment Service (HIRA) claims database (Seoul, Korea). Serious adverse events (SAE) were defined as any diagnostic code at the time of hospitalization within 12 weeks from a statin prescription date, regardless of causality. Among statin users, RRs were calculated to compare the proportion of rosuvastatin-specific SAE pairs for rosuvastatin users with the corresponding proportion of drug-SAE pairs for users of other statins. Any SAE for which the lower limit of the RR's 95% ...

top  

  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis. Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial.

Conclusion-Cholesterol lowering with rosuvastatin 40 mg did not reduce the progression of AS in patients with mild to moderate AS; thus, statins should not be used for the sole purpose of reducing the progression of AS. Clinical Trial Registration Information-URL: http://www.controlled-trials.com/. Clinical trial registration number: ISRCTN 32424163. PMID: 20048204 [PubMed - as supplied by publisher] (Source: Circulation)

top  

  HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.

Authors: Suh JW, Choi DJ, Chang HJ, Cho YS, Youn TJ, Chae IH, Kim KI, Kim CH, Kim HS, Oh BH, Park YB Hypertension is associated with endothelial dysfunction and increased cardiovascular risk. Caveolin-1 regulates nitric oxide (NO) signaling by modulating endothelial nitric oxide synthase (eNOS). The purpose of this study was to examine whether HMG-CoA reductase inhibitor improves impaired endothelial function of the aorta in spontaneous hypertensive rat (SHR) and to determine the underlying mechanisms involved. Eight-week-old male SHR were assigned to either a control group (CON, n=11) or a rosuvastatin group (ROS, n=12), rosuvastatin (10 mg/kg/day) administered for eight weeks. Abdominal aortic rings were prepared and responses to acetylcholine (10(-9)-10(-4) M) were determined in vit...

top  

  FDA Panel Backs Rosuvastatin for High hsCRP

GAITHERSBURG, MD. — Findings from the JUPITER study convinced a Food and Drug Administration advisory panel that the benefits of rosuvastatin for the primary prevention of cardiovascular disease outweighed the risks in a new target population—those with high hsCRP levels. (Source: Cardiology News)

top  

  News From the FDA

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12–4, with 1 abstention, that data support the use of rosuvastatin for the primary prevention of major cardiovascular adverse events in men aged 50 years and older and in women aged 60 years and older with a fasting LDL cholesterol level below 130 mg/dL, high-sensitivity C-reactive protein (hsCRP) level of 2.0 mg/L or more, triglyceride level below 500 mg/dL, and no prior history of cardiovascular events or disease. (Source: Internal Medicine News)

top  

  Statin Prevents Events in Patients With IFG

Major Finding: In patients with impaired fasting glucose, rosuvastatin was associated with a 32% reduction in the risk of major adverse coronary events, but also with increased new-onset diabetes. (Source: Clinical Endocrinology News)

top  

  FDA Panel Sees Benefit in Rosuvastatin for High hsCRP

GAITHERSBURG, MD. — Findings from the JUPITER study convinced a Food and Drug Administration advisory panel that the benefits of rosuvastatin for the primary prevention of cardiovascular disease outweighed the risks in a new target population—those with high hsCRP levels. (Source: Clinical Endocrinology News)

top  

  Panel Supports Rosuvastatin for High hsCRP

GAITHERSBURG, MD. — Findings from the JUPITER study were persuasive enough to convince a Food and Drug Administration advisory panel that the benefits of rosuvastatin for the primary prevention of cardiovascular disease outweighed the risks in a new target population. (Source: Family Practice News)

top  

  More than 50% reduction in ischaemic stroke with rosuvastatin in the JUPITER study.

Authors: PMID: 20224853 [PubMed - in process] (Source: Cardiovascular Journal of Africa)

top  

  FDA approves Crestor for people who have no health problem to correct

(NaturalNews) Big Pharma has been trending this direction for a long time: marketing medicines to people who don't need them and who have nothing wrong with their health. It's all part of a ploy to position prescription drugs as nutrients -- things you need to take on a regular basis in order to prevent disease.The FDA recently gave its nod of approval on the matter, announcing that Crestor can now be advertised and prescribed as a "preventive" medicine. No longer does a patient need to have anything wrong with them to warrant this expensive prescription medication: They only need to remember the brand name of the drug from television ads.This FDA approval for the marketing of Crestor to healthy people is a breakthrough for wealthy drug companies. Selling drugs only to people who are sick ...

top  

  Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study.

Authors: Stefanutti C, D'Alessandri G, Russi G, De Silvestro G, Zenti MG, Marson P, Belotherkovsky D, Vivenzio A, Di Giacomo S LDL-apheresis (LDLa) efficacy in the treatment of symptomatic HyperLp(a)lipoproteinemia -HyperLp(a)- has been studied in a multicentre trial. After 3.1+/-2.7 years of weekly and biweekly treatment, the data from 19 patients (males:12; females:7; aged 53.8+/-9.3 years; mean body mass index: 24.6+/-2.3 Kg/m(2)) were evaluated. Data were collected using the same questionnaire shared by 5 participating centres. A total of 2331 procedures were performed. A mean of 3593.7+/-800.3 ml of plasma or 8115.3+/-2150.1 ml of blood, depending upon the technique used (H.E.L.P., D.A.LI., Dextransulphate, Lipocollect 200), was regularly treated on average every 10.1+/-2.6 days. ...

top  

  Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)

Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual patient data pooled analysis was performed of 32,258 patients in studies comparing the efficacy of rosuvastatin with that of atorvastatin or simvastatin. The impact of increasing dose on lowering LDL cholesterol, triglycerides, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B was investigated. Doubling the dose of each statin was accompanied by a 4% to 7% greater degree of lowering of all atherogenic lipids. A stronger correlation was observed between changes in LDL cholesterol and non-HD...

top  

  Meta-analysis: Heart failure benefits of different statins

Source: Am J Cardiology Area: News A meta-analysis of placebo-controlled randomised trials featured in the American Journal of Cardiology has found that different statins have different effects on heart failure(HF).   The researchers searched CENTRAL, mRCT, and PubMed for eligible studies that prospectively randomised patients with HF to statins or placebo. Primary end points were all-cause mortality, cardiovascular mortality, hospitalisation for worsening HF, adverse drug events, and changes in left ventricular ejection fraction (LVEF). Data was pooled using the random effects model with summary effect estimates (95% confidence intervals).   Ten studies (10,192 patients; mean age 69 years; 78% male) with follow-up from 3 to 47 months met the inclusion criteria. Three tr...

top  

  Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein. Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).

Conclusion-Rosuvastatin reduces by more than half the incidence of ischemic stroke among men and women with low levels of low-density lipoprotein cholesterol levels who are at risk because of elevated levels of high-sensitivity C-reactive protein. Clinical Trial Registration-clinicaltrial.gov. Unique identifier: NCT00239681. PMID: 20026779 [PubMed - as supplied by publisher] (Source: Circulation)

top  

  An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial

Conclusion This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure. (Source: European Journal of Heart Failure)

top  

  Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis (1)

In this study HDL cholesterol levels were predictive of major cardiovascular events even among patients with LDL cholesterol levels below 1.8mmol/l. (Source: Atherosclerosis)

top  

  Statins May Soon Be Given to Those With Excess Inflammation

An FDA panel OK'd Crestor for those with normal cholesterol but excess inflammation. Is it for you? (Source: U.S. News - Health)

top  

  Rosuvastatin Better Than Pravastatin for Protease-Inhibitor-Related Dyslipidemia

Rosuvastatin is better than pravastatin at lowering levels of LDL cholesterol and triglycerides in HIV-infected patients with protease-inhibitor (PI)-associated dyslipidemia, according to an article in the January 2nd issue of AIDS. Reuters Health Information (Source: Medscape Today Headlines)

top  

  FDA committee gives nod to broadening use of Crestor

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Wednesday voted (12 yes, four no and one abstention) that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of Crestor (rosuvastatin calcium) in more individuals for more conditions. (Source: Cardiovascular Business News)

top  

  Crestor may be prescribed to healthy

WASHINGTON, Dec. 16 (UPI) -- A panel of the U.S. Food and Drug Administration voted to recommend the cholesterol lowering drug Crestor be approved for those with inflammation. (Source: Health News - UPI.com)

top  

  Rosuvastatin more effective than pravastatin in HIV-1-infected patients receiving a boosted protease inhibitor

Source: Reuters Health News Area: News According to a randomised controlled study published in the journal AIDS, rosuvastatin 10 mg/day is more effective than pravastatin 40 mg/day at lowering levels of LDL cholesterol and triglycerides in HIV-1-infected patients receiving a boosted protease inhibitor (PI).   It is well documented that HIV infection and its treatment with PIs, especially when boosted with ritonavir, can cause dyslipidaemia, and with the exception of fluvastatin, pravastatin and rosuvastatin, all statins interact with PI metabolism via CYP450. In these patients, pravastatin is recommended for patients with PI-associated dyslipidaemia.   In this randomised controlled trial, researchers randomised 88 HIV-1-infected patients treated with boosted ritonavir, t...

top  

  US FDA panel backs wider use of rosuvastatin (CrestorT)

Source: PharmaTimes, BioSpace Area: News The U.S. Food and Drug Administration (FDA) Endocrinology and Metabolic Drugs Advisory Committee reached a positive vote ( 12 yes, 4 no, and 1 abstention) in support of the use of rosuvastatin (CrestorT) in certain patients who have no prior history of cardiovascular or cerebrovascular events or coronary heart disease.   The decision was based on a review of data from the 17,802 -patient JUPITER study which demonstrated that rosuvastatin cut deaths, heart attacks and strokes in middle-aged people with low-to-normal cholesterol but elevated high-sensitivity levels of C-reactive protein, an indicator of inflammation associated with heart disease.   The panellists also looked at safety data which revealed a 27% higher rate of diabete...

top  

  FDA Advisory Panel Votes in Favor of Broadened Rosuvastatin Indication

The advisory panel voted 12 to 4 in favor of expanding the indication for rosuvastatin to include men and women >50 and >60 years old, respectively, with elevated CRP levels, normal LDL-cholesterol levels, and without any other cardiovascular-disease risk equivalents. Heartwire (Source: Medscape Today Headlines)

top  

  Health Buzz: FDA Panel Says Crestor Benefits People With Normal Cholesterol

Combating symptoms of menopause using hormones; dietary changes to make as you age (Source: U.S. News - Health)

top  

  Favorable Vote from FDA Advisory Committee on Benefit/Risk of Crestor (rosuvastatin calcium) in JUPITER Study

WILMINGTON, Del., Dec. 15 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient... (Source: Drugs.com - Pharma News)

top  

  FDA Panel Backs New Use For Astrazeneca's Crestor

From Associated Press (December 15, 2009) GAITHERSBURG, Maryland--Federal health advisers said Tuesday that expanded use of AstraZeneca’s cholesterol pill Crestor can benefit patients with healthy cholesterol levels by preventing heart attack,... (Source: Drugs.com - Pharma News)

top  

  FDA Advisers Recommend Expanding Crestor to Patients Without High Cholesterol

(Source: Physician's First Watch current issue)

top  

  Favorable Vote From FDA Advisory Committee On Benefit/Risk Of CRESTOR(R) (rosuvastatin Calcium) In JUPITER Study

The U.S... (Source: Health News from Medical News Today)

top  

  Favorable Vote From FDA Advisory Committee On Benefit/Risk Of CRESTOR(R) (rosuvastatin Calcium) In JUPITER Study

The U.S... (Source: Cardiovascular / Cardiology News From Medical News Today)

top  

  FDA Panel Backs Statin for Primary Prevention

WASHINGTON (MedPage Today) -- An FDA advisory panel has overwhelminingly recommended that rousuvastatin (Crestor) be approved for use in patients with no history of heart disease as long as the patients have an elevated level of the inflammatory marker C-reactive protein. (Source: MedPage Today Cardiovascular)

top  

  FDA panel backs Crestor for heart attack, stroke prevention

Federal health advisers said Tuesday that expanded use of AstraZeneca's cholesterol pill Crestor can benefit patients with healthy ... (Source: USATODAY.com Health)

top  

  FDA advisory panel votes in favor of broadened rosuvastatin indication

The advisory panel voted 12 to 4 in favor of expanding the indication for rosuvastatin to include men and women >50 and >60 years old, respectively, with elevated CRP levels, normal... For complete story visit theheart.org. (Source: theHeart.org)

top  

  U.S. panel backs wider use of AstraZeneca's Crestor

GAITHERSBURG, Maryland (Reuters) - AstraZeneca won a U.S. panel's support on Tuesday for its bid to promote the cholesterol-lowering pill Crestor to people with healthy cholesterol levels but have other risks of heart disease. (Source: Reuters: Health)

top  

  FDA Panel Backs Wider Use of Crestor

An FDA panel backed wider use of AstraZeneca's cholesterol-lowering drug Crestor. (Source: WSJ.com: Health)

top  

  Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population: Insights From the ARIC (Atherosclerosis Risk in Communities) Study

Objectives: The purpose of this study is to describe the proportion of “JUPITER-eligible” (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) individuals and clinical outcomes of individuals based on high-sensitivity C-reactive protein (hs-CRP) and low-density lipoprotein cholesterol (LDL-C) strata in the ARIC (Atherosclerosis Risk in Communities) study.Background: Questions remain after the JUPITER study, including whether the observed cardiovascular disease (CVD) event rates would persist with time and how these event rates would compare with other populations (lower hs-CRP and/or higher LDL-C levels).Methods: After stratification into 4 groups based on LDL-C and hs-CRP levels, with cutoffs at 130 mg/dl and 2.0 mg/l, respectively, incid...

top  

  FDA Panel Readies to Review Expanded Rosuvastatin Label

The panel will review the company's bid to broaden the labeling for this statin to include people with normal LDL levels but high CRP. The application is based on the positive findings from the JUPITER trial. Heartwire (Source: Medscape Today Headlines)

top  

  FDA panel readies to review expanded rosuvastatin label

The panel will review the company's bid to broaden the labeling for this statin to include people with normal LDL levels but high CRP. The application is based on the positive findings from the JUPITER trial. (Source: theHeart.org)

top  

  FDA panel readies to review expanded rosuvastatin label

The panel will review the company's bid to broaden the labeling for this statin to include people with normal LDL levels but high CRP. The application is based on the positive findings from the... For complete story visit theheart.org. (Source: theHeart.org)

top  

  U.S. panel to weigh safety of AstraZeneca's Crestor

WASHINGTON (Reuters) - U.S. regulators see benefits to using an AstraZeneca Plc cholesterol drug in a vast new group of patients but will ask outside advisers to probe various safety issues, documents released on Friday said. (Source: Reuters: Health)

top  

  FDA to weigh safety of AstraZeneca's Crestor

WASHINGTON (Reuters) - U.S. regulators will ask an advisory panel to consider findings of diabetes and other safety issues as they weigh wider use of AstraZeneca Plc's AZN.L cholesterol-lowering pill Crestor, documents released on Friday said. (Source: Reuters: Health)

top  

  FDA Confirms Benefits of Crestor In More Patients

From Associated Press (December 11, 2009) WASHINGTON--Federal scientists say AstraZeneca ’s cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns... (Source: Drugs.com - Pharma News)

top  

  FDA says cholesterol pill Crestor curbs heart problems in patients, but notes diabetes risk

WASHINGTON (AP) — Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain. In documents posted online Friday,... (Source: OrlandoSentinel: Medical Research)

top  

  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This generally well-conducted review concluded that statin use in patients without established cardiovascular disease, but with cardiovascular risk factors, was associated with significantly improved survival and large reductions in the risk of major cardiovascular events. This conclusion reflected the results of an appropriate synthesis of large, high-quality trials and is likely to be reliable. [Included studies used pravastatin, lovastatin, atorvastatin, simvastatin or rosuvastatin.] CRD Commentary: The review question was clear and supported by specific inclusion criteria. The authors searched several relevant databases and this reduced their chances of omitting relevant studies. No systematic attempts to locate un...

top  

  Small leucine-rich proteoglycans in atherosclerotic lesions: Novel targets of chronic statin treatment?

Conclusions: Long term treatment with rosuvastatin caused pronounced remodelling of atherosclerotic plaque matrix characterized specifically by enrichment with SLRP and formation of a condensed collagen matrix. Therefore, decorin and biglycan might represent novel targets of statin treatment that contribute to a stable plaque phenotype. PMID: 20015203 [PubMed - as supplied by publisher] (Source: J Cell Mol Med)

top  

  Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure

Although statins have been shown to improve outcomes in retrospective analyses of patients with heart failure (HF), recent randomized placebo-controlled trials have shown mixed results. The goal of this study was to systematically review randomized trials comparing statins to placebo for HF and compare the impact of different statins. CENTRAL, mRCT, and PubMed were searched for eligible studies that prospectively randomized patients with HF to statins or placebo. Primary end points were all-cause mortality, cardiovascular mortality, hospitalization for worsening HF, adverse drug events, and changes in left ventricular ejection fraction (LVEF). Pooling was performed with random effect methods with summary effect estimates (95% confidence intervals). Ten studies (10,192 patients) with follow...

top  

  Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong.

CONCLUSION: Rosuvastatin was effective in improving LDL-cholesterol goal attainment and lowering LDL-cholesterol and triglyceride (TG) levels in either newly started or switched patients. PMID: 20092783 [PubMed - in process] (Source: Chinese Medical Journal)

top  

  Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.

Authors: Bologa R, Levine D, Parker T, Gordon B, Lanto A, Cheigh J, Stenzel K, Rubin A, Patients undergoing dialysis treatment have a high incidence of dyslipidemia. Rosuvastatin is a potent statin drug that improves overall lipid profiles in dyslipidemic patients. However, the pharmacokinetics of rosuvastatin has not been studied in patients with end-stage kidney disease undergoing chronic peritoneal dialysis (PD). The goals of this study are to determine the pharmacokinetics and tolerability of a single oral dose of rosuvastatin in patients undergoing continuous ambulatory PD (CAPD). This was a nonrandomized, open-label, 1-week trial. Ten stable PD patients were given a single oral dose of rosuvastatin (10 mg). Serial blood samples were obtained over the next 48 hours, and the patie...

top  

  A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial

Conclusion: We observed no superiority of either treatment for the ESC-03 lipid targets. Rosuvastatin 10mg lowered mean cholesterol more effectively than simvastatin and achieved better results for the latest, more stringent, ESC target. (Source: European Journal of Cardiovascular Prevention and Rehabilitation)

top  

  Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins.

Conclusions: These results identify key membrane transporters as modulators of skeletal muscle statin exposure and toxicity. PMID: 19940267 [PubMed - as supplied by publisher] (Source: Circulation Research)

top  

  Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category

Metabolic Syndrome and Related Disorders , Vol. 0, No. 0. (Source: Metabolic Syndrome and Related Disorders)

top  

  AHA: Drilling Down in JUPITER Confirms Benefit for Women (CME/CE)

ORLANDO (MedPage Today) -- A subset analysis of data from the JUPITER trial indicates that apparently healthy women treated with rosuvastatin (Crestor) reduced their relative risk of major cardiovascular events by 46%, slightly higher than the 42% reduction seen in men. (Source: MedPage Today Cardiovascular)

top  

  Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure

Conclusion These findings suggest that hydrophilic rosuvastatin but not lipophilic simvastatin increases adiponectin and decreases HbA1c levels in patients with NICHF. (Source: European Journal of Heart Failure)

top  

  Crestor® Reduced Risk Of Cardiovascular Events In Women By Nearly Half In New Analysis Of Jupiter Study

A new analysis of 6,801 women in the JUPITER study showed CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced cardiovascular (CV) events (defined as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by nearly half (46 percent; p=0.002 vs. (Source: Cardiovascular / Cardiology News From Medical News Today)

top  

  Crestor® Reduced Risk Of Cardiovascular Events In Women By Nearly Half In New Analysis Of Jupiter Study

A new analysis of 6,801 women in the JUPITER study showed CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced cardiovascular (CV) events (defined as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by nearly half (46 percent; p=0.002 vs. (Source: Health News from Medical News Today)

top  

  AURORA: Is There a Role for Statin Therapy in Dialysis Patients?

Commentary on Fellstrom BC, Jardine AG, Schmieder RE, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407. (Source: American Journal of Kidney Diseases)

top  

  Crestor shows equal or better benefit to women

ORLANDO, Florida (Reuters) - A fresh look at data from a landmark study showed that AstraZeneca's powerful cholesterol fighter Crestor dramatically cut deaths, heart attacks and strokes in women at least as much as in men, providing new evidence of the drug's benefits in a previously understudied population. (Source: Reuters: Health)

top  

  Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). A Retrospective Analysis.

Conclusion-In this retrospective hypothesis-generating study, we found a significant interaction between hs-CRP and the effect of rosuvastatin for most end points whereby rosuvastatin treatment was associated with better outcomes in patients with hs-CRP >/=2.0 mg/L. Clinical Trial Registration Information-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00206310. PMID: 19917888 [PubMed - as supplied by publisher] (Source: Circulation)

top  

  Eligibility for Statin Therapy by the JUPITER Trial Criteria and Subsequent Mortality

Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. The aim of this study was to determine the prevalence of eligibility and mortality in a general population sample on the basis of eligibility for statin treatment using the JUPITER criteria. The study group consisted of 30,229 participants in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of US African American and white participants aged ≥45 years, enrolled in their homes from 2003...

top  

  Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis

Conclusions: Statins do not appear to demonstrate a ‘class effect’ on IS in patients without diabetes. Differences between individual statins likely exist that may partially explain the findings of previously conducted meta-analyses examining the impact of statins on the development of diabetes. (Source: Diabetes Research and Clinical Practice)

top  

  Rosuvastatin Attenuates Ang II--Mediated Cardiomyocyte Hypertrophy via Inhibition of LOX-1

3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, also known as statins, have been shown to reduce cardiac remodeling. Angiotensin II (Ang II) type 1 receptor (AT1R) and oxidized low-density lipoprotein (ox-LDL) via its lectin-like ox-LDL receptor (LOX-1) are major stimuli for cardiomyocyte growth. We postulated that rosuvastatin, a potent HMG-CoA reductase inhibitor, may reduce Ang II—mediated cardiomyocyte growth via AT1R and LOX-1 inhibition. HL-1 adult mouse cardiomyocytes were incubated overnight in serum-free medium, and then treated with rosuvastatin, the AT1R inhibitor losartan or anti-LOX-1 antibody for 3 hours. The cells were then stimulated with Ang II. We measured cardiomyocyte growth, and associated intracellular redox signals using reverse transcription&mda...

top  

  Effect of Targeting Mitogen-Activated Protein Kinase on Cardiac Remodeling in Rats

Conclusions: Targeting MAPK might represent a useful therapeutic avenue to ameliorate cardiac remodeling and support the notion that atRA and statins are potential candidates for the prevention and therapy of cardiac remodeling. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)

top  

  Highly stereoselective hydrogenations-As key-steps in the total synthesis of statins.

Authors: Andrushko N, Andrushko V, Tararov V, Korostylev A, König G, Börner A Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long-term benefits. They are administered as diastereo- and enantiomerically pure compounds. We summarize here two new approaches for the total synthesis of the most important representatives, atorvastatin, and rosuvastatin, based on highly stereoselective hydrogenations as key-steps. Chirality 2010. (c) 2009 Wiley-Liss, Inc. PMID: 19899159 [PubMed - as supplied by publisher] (Source: Chirality)

top  

  Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin: A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)

Conclusions: Patients with heart failure due to ischemic heart disease who have NT-proBNP values (Source: Journal of the American College of Cardiology)

top  

  Achievement of ldl-c levels with three different drug strategies after failure of simvastatin 40mg

Background: NICE lipid guidelines recommend simvastatin (S) 40mg as initial therapy, after lifestyle changes, in most patients requiring treatment. When desirable levels have not been met, increasing the dose, switching to a more potent statin or adding ezetimibe (E) can be considered. The addition of E to S was compared with switching to atorvastatin (A) or rosuvastatin (R) in a randomised, double-blind trial. (Source: Atherosclerosis)

top  

  Statin Is Mildly Protective Against AF in Heart Failure

BARCELONA — Rosuvastatin exerted a “modest” preventive effect against the occurrence of atrial fibrillation in patients with chronic heart failure, according to a secondary analysis of the Italian GISSI-Heart Failure study. (Source: Cardiology News)

top  

  Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of G(h).

Authors: Choi EY, Chang W, Lim S, Song BW, Cha MJ, Kim HJ, Choi E, Jang Y, Chung N, Hwang KC Statins have recently been shown to produce anti-cardiac hypertrophic effects via the regulation of small GTPases. However, the effects of statins on G protein-mediated cardiac hypertrophy, which is the main pathway of cardiac hypertrophy, have not yet been studied. We sought to evaluate whether statin treatment directly suppresses cardiac hypertrophy through a large G protein-coupled pathway regardless of the regulation of small GTPases. Using neonatal rat cardiomyocytes, we evaluated norepinephrine-induced cardiac hypertrophy for suppressibility of rosuvastatin and the pathways involved by analyzing total protein/DNA content, cell surface area, immunoblotting and RT-PCR for the signal transdu...

top  

  [From lipid target values to JUPITER study. Importance of the achievement of lipid levels specified by the guidelines and deficiencies in the present practice.]

Authors: Márk L, Katona A In Hungary the life expectancy have increased by 4.14 years between 1993 and 2006 and the improvement of cardiovascular mortality contributed to this with 1.85 years. Lipid lowering therapy and achievement of target lipid levels have become recently a crucial point of cardiovascular prevention. Despite the improving tendency the rate of achieving LDL-cholesterol goal is not higher than 1/3 and its main cause seems to be the fact that greater part of the physicians (56% of them in year 2007) - seeing the results with not convenient lipid levels - yield to it, do not modify the current treatment. However, there is growing evidence that the lower LDL-cholesterol level improves not only the clinical outcome but it is cost-effective as well. The most important...

top  

  In vitro interactions between primycin and different statins in their effects against some clinically important fungi.

Authors: Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C The in vitro antifungal activities of primycin and various statins against some opportunistic pathogenic fungi were investigated. Primycin completely inhibited the growth of Candida albicans (MIC: 64 microg ml(-1)) and Candida glabrata (MIC: 32 microg ml(-1)), and was very effective against Paecilomyces variotii (MIC: 2 microg ml(-1)), but it had little effect on Aspergillus fumigatus, Aspergillus flavus or Rhizopus oryzae (MIC: >64 microg ml(-1)). The fungi exhibited different degrees of sensitivity to the statins; fluvastatin and simvastatin exerted potent antifungal activities against a wide variety of clinically important fungal pathogens. Atorvastatin, rosuvastatin and lovastatin were slightly effective again...

top  

  Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.

CONCLUSIONS: Prophylactic treatment for yellow plaque and thrombus formation are extremely important in the development of early and late SVG disease. Aggressive lipid controlling therapy is quite attractive to avoid post CABG SVG disease and may be effective to maintain the long-term graft patency. PMID: 19853088 [PubMed - in process] (Source: The Annals of Thoracic Surgery)

top  

  Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples.

Authors: Lee HB, Peart TE, Lewina Svoboda M, Backus S Rosuvastatin (RST) and atorvastatin (ATO) are prescription drugs and members in the statin family used for the treatment of elevated cholesterol levels. A method using solid-phase extraction and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the determination of ATO, RST and its metabolite rosuvastatin lactone (RSTL) in sewage and surface water samples has been developed. In the influent and effluent samples collected from 11 sewage treatment plants located in Ontario, Canada, ATO, RST, and RSTL were detected in all samples with median concentrations of 166ngL(-1) (influent) and 77ngL(-1) (effluent) for ATO, 448ngL(-1) (influent) and 324ngL(-1) (effluent) for RST, as well as 158ngL(-1) (influent) and 41ngL(-1) (efflue...

top  

  Cosmic Effect of Rosuvastatin in COSMOS.

Authors: Adachi T, Ohsuzu F PMID: 19851029 [PubMed - in process] (Source: Circulation Journal)

top  

  Efficacy of Aggressive Lipid Controlling Therapy for Preventing Saphenous Vein Graft Disease [ORIGINAL ARTICLES: ADULT CARDIAC]

Conclusions Prophylactic treatment for yellow plaque and thrombus formation are extremely important in the development of early and late SVG disease. Aggressive lipid controlling therapy is quite attractive to avoid post CABG SVG disease and may be effective to maintain the long-term graft patency. (Source: The Annals of Thoracic Surgery)

top  

  What Risks Are Associated With High-Dose Rosuvastatin?

Although some clinicians prescribe off-label, high-dose rosuvastatin, such dosing may place patients at higher risk for myopathy and renal toxicity. Medscape Pharmacists (Source: Medscape Cardiology Headlines)

top  

  Astra nets FDA nod for Crestor in younger patients

The FDA has approved AstraZeneca’s Crestor (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia, when diet therapy fails to reduce elevated cholesterol. (Source: Cardiovascular Business News)

top  

  Rosuvastatin Cleared for Pediatric FH

The FDA has approved rosuvastatin for use in children aged 10 to 17 years old with familial hypercholesterolemia. Heartwire (Source: Medscape Today Headlines)

top  

  CRESTOR (Rosuvastatin Calcium) Tablet, Film Coated [AstraZeneca Pharmaceuticals LP]

Updated Date: Oct 20, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes.

This study was designed to elucidate, which transporters take part in the biliary clearance of rosuvastatin using sandwich cultured primary rat hepatocytes. The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Mrp2 inhibitors decreased the biliary efflux of rosuvastatin most potently by 78.9%, 35%, 54.1%; benzbromarone, probenecid, sulfasalazine, respectively, while Bcrp and Bsep inhibitors showed much less effect (29.1%, 23.0% ,30.0%; Ko 134, mitoxanthrone, n...

top  

Top Viagra Store

A first shop in the series of one-pill shops is rightfully viagra-targeted. The index page offers only Viagra, both generic and original.It is possible to purchase other ED products from other pagers, but the main accent is on Viagra.

top-viagra-store.com

Indian Meds

A most recent indian-themed, ethnic site. Includes generic and original (brand) products. al our standard navigational tools and support options are available. This site converts nicely on general pharmaceutical traffic as it has products for vurtually any need.

indianmeds.org

Friendly ED Pharmacy

Many ED customers are anxious about the status their orders. This special friendly site is here to solve the problem. "State of the art" design features high usability and clearly visible support options. All this helps to satisfy even the most demanding customer and results in increased sales ratio.

friendly-ed-pharmacy.com

Popular ED Products

This ED site offers simplistic design that gets right to the point - this IS the site for ED. Popular ED list the top selling products and converts best on ED-targeted, pill-specific traffic.

popular-ed-products.com

Perfect ED Store

This site is just right for ED customers. All ED products are conveniently listed at main page, allowing to make an easy choice. Our regular Sample Pills Offer is emphasized here. Customers can try new products and are likely to return for more refills.

perfect-ed-store.com

Worlds Best Pharmacy

The name says it all. This is the best online pharmacy on the web. The index page is set to show the most polular ED products, while the menu and quicksearch allow to find products in other categories.

worlds-best-pharmacy.com

Delhi Drugs

This Indian-themed site offers a completely new design. All our generic products are availabe and can easily be located with the help of quicksearch feature. Includes our latest shopping engine and billing page.

www.delhi-drugs.com

Indian Generics

Many customers are looking for Indian drugs, and this site is designed specifically for such customers. It includes many generic products, modern design, translated into 7 languages and prices in both USD and Euros. Also it uses our latest shopping engine and billing page.

www.indian-generics.com